Insider Selling: DexCom (NASDAQ:DXCM) Director Sells $130,231.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Nicholas Augustinos sold 1,550 shares of the company’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $84.02, for a total transaction of $130,231.00. Following the completion of the transaction, the director owned 35,832 shares of the company’s stock, valued at approximately $3,010,604.64. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Nicholas Augustinos also recently made the following trade(s):

• On Tuesday, September 15th, Nicholas Augustinos sold 6,539 shares of DexCom stock. The shares were sold at an average price of $84.04, for a total value of $549,537.56.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $89.35 on Friday. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59. The company has a market cap of $33.72 billion, a PE ratio of 35.32, a P/E/G ratio of 1.47 and a beta of 1.42. The stock has a 50 day simple moving average of $84.10 and a 200-day simple moving average of $73.28. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm’s revenue was up 13.1% compared to the same quarter last year. During the same period last year, the firm earned $0.48 EPS. On average, equities research analysts forecast that DexCom, Inc. will post 2.64 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Royal Bank Of Canada lifted their price objective on shares of DexCom from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Raymond James Financial restated a “strong-buy” rating and set a $94.00 price target on shares of DexCom in a research report on Friday, July 31st. Canaccord Genuity Group set a $90.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Monday, August 3rd. Wells Fargo & Company boosted their target price on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Finally, Piper Sandler restated an “overweight” rating and issued a $95.00 target price (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $89.08.

Institutional Trading of DexCom

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. MassMutual Private Wealth & Trust FSB grew its position in DexCom by 15.4% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after buying an additional 153 shares during the last quarter. V Square Quantitative Management LLC increased its holdings in shares of DexCom by 1.8% in the first quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock valued at $604,000 after buying an additional 172 shares in the last quarter. Essex Financial Services Inc. lifted its position in shares of DexCom by 5.7% during the 1st quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after acquiring an additional 175 shares during the last quarter. Gabelli Funds LLC lifted its position in shares of DexCom by 0.4% during the 4th quarter. Gabelli Funds LLC now owns 50,200 shares of the medical device company’s stock valued at $3,332,000 after acquiring an additional 200 shares during the last quarter. Finally, One Wealth Map LLC boosted its stake in shares of DexCom by 5.6% during the 1st quarter. One Wealth Map LLC now owns 4,900 shares of the medical device company’s stock worth $301,000 after acquiring an additional 261 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.